NZ714288A - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents
Extended-release formulation for reducing the frequency of urination and method of use thereofInfo
- Publication number
- NZ714288A NZ714288A NZ714288A NZ71428813A NZ714288A NZ 714288 A NZ714288 A NZ 714288A NZ 714288 A NZ714288 A NZ 714288A NZ 71428813 A NZ71428813 A NZ 71428813A NZ 714288 A NZ714288 A NZ 714288A
- Authority
- NZ
- New Zealand
- Prior art keywords
- urination
- frequency
- reducing
- extended
- release formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Abstract
Methods and pharmaceutical compositions for reducing the frequency of urination are disclosed. The composition may include zolpidem and one or more analgesic agents optionally further including an antimuscarinic agent, antidiuretic agent or spasmolytic. The composition may be formulated for immediate release, delayed release, extended release or combination thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/424,000 US8236857B2 (en) | 2010-07-08 | 2012-03-19 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US13/487,348 US20120244221A1 (en) | 2010-07-08 | 2012-06-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ714288A true NZ714288A (en) | 2016-12-23 |
Family
ID=49223209
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ712594A NZ712594A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ718163A NZ718163A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ714288A NZ714288A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ628079A NZ628079A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ712594A NZ712594A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ718163A NZ718163A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ628079A NZ628079A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP2827852A4 (en) |
JP (5) | JP2015510928A (en) |
KR (4) | KR20140134333A (en) |
CN (4) | CN107157991A (en) |
AU (4) | AU2013235518B2 (en) |
BR (2) | BR112014020271A8 (en) |
CA (2) | CA2866853A1 (en) |
HK (3) | HK1204553A1 (en) |
MX (3) | MX2014011128A (en) |
MY (2) | MY174090A (en) |
NZ (6) | NZ712594A (en) |
RU (3) | RU2669565C2 (en) |
SG (2) | SG11201500408VA (en) |
WO (2) | WO2013142197A1 (en) |
ZA (2) | ZA201405862B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
US9814753B2 (en) | 2013-07-23 | 2017-11-14 | Serenity Pharmaceuticals Llc | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist |
KR20170010440A (en) * | 2014-06-06 | 2017-01-31 | 웰즐리 파마슈티컬스 엘엘씨 | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
KR101809908B1 (en) | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | Pharmaceutical composition comprising 5-α reductase inhibitor |
CN106999538A (en) * | 2014-11-20 | 2017-08-01 | 阿勒根公司 | Method and composition comprising minirin Yu alpha-2 adrenoceptor antagonist-combination |
KR20180066113A (en) * | 2015-09-30 | 2018-06-18 | 웰즐리 파마슈티컬스 엘엘씨 | Composition for reducing urinary frequency |
JP2018529711A (en) * | 2015-09-30 | 2018-10-11 | ウェルズリー ファーマスーティカルズ、エルエルシー | Composition for reducing the frequency of urination, and methods of making and using the same |
CN105238124B (en) * | 2015-11-16 | 2018-02-09 | 太仓东能环保设备有限公司 | A kind of antibacterial mastic powder |
JP6294924B2 (en) | 2016-09-05 | 2018-03-14 | 株式会社Subaru | Vehicle travel control device |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2546399A (en) * | 1998-02-10 | 1999-08-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
US20020102309A1 (en) * | 1999-09-14 | 2002-08-01 | Jane C. I. Hirsh | Controlled release formulation for administration of an anti-inflammatory naphthalene derivative |
DE10116978A1 (en) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa opiate agonists for the treatment of diseases of the bladder |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
KR20050005410A (en) * | 2002-02-19 | 2005-01-13 | 파마시아 코포레이션 | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
RU2004135563A (en) * | 2002-06-07 | 2005-06-10 | Яманоути Фармасьютикал Ко.,Лтд. (Jp) | MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER |
US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
EP1605929B1 (en) * | 2003-03-21 | 2014-04-23 | McNeil-PPC, Inc. | Non-steroidal anti-inflammatory drug dosing regimen |
EP1492519B1 (en) * | 2003-03-21 | 2006-11-15 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators |
EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
EP1792629A4 (en) * | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | Preventives/remedies for stress urinary incontinence and method of screening the same |
EP1898930A4 (en) * | 2005-06-17 | 2009-12-09 | Dynamis Therapeutics Inc | Treatment of inflammatory conditions |
US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
ZA200802811B (en) * | 2005-09-02 | 2009-09-30 | Theravida Inc | Therapy for the treatment of disease |
US20120064159A1 (en) * | 2009-05-28 | 2012-03-15 | Aptapharma, Inc. | Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
US20120244221A1 (en) * | 2010-07-08 | 2012-09-27 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
-
2013
- 2013-03-13 RU RU2014142025A patent/RU2669565C2/en not_active IP Right Cessation
- 2013-03-13 NZ NZ712594A patent/NZ712594A/en not_active IP Right Cessation
- 2013-03-13 WO PCT/US2013/030901 patent/WO2013142197A1/en active Application Filing
- 2013-03-13 SG SG11201500408VA patent/SG11201500408VA/en unknown
- 2013-03-13 CA CA2866853A patent/CA2866853A1/en not_active Abandoned
- 2013-03-13 MX MX2014011128A patent/MX2014011128A/en unknown
- 2013-03-13 CN CN201710373440.5A patent/CN107157991A/en active Pending
- 2013-03-13 CN CN201380015062.3A patent/CN104302284A/en active Pending
- 2013-03-13 KR KR1020147029163A patent/KR20140134333A/en not_active Application Discontinuation
- 2013-03-13 NZ NZ718163A patent/NZ718163A/en not_active IP Right Cessation
- 2013-03-13 NZ NZ714288A patent/NZ714288A/en not_active IP Right Cessation
- 2013-03-13 NZ NZ630471A patent/NZ630471A/en not_active IP Right Cessation
- 2013-03-13 JP JP2015501754A patent/JP2015510928A/en active Pending
- 2013-03-13 BR BR112014020271A patent/BR112014020271A8/en not_active Application Discontinuation
- 2013-03-13 AU AU2013235518A patent/AU2013235518B2/en not_active Ceased
- 2013-03-13 MY MYPI2014702434A patent/MY174090A/en unknown
- 2013-03-13 EP EP13763764.1A patent/EP2827852A4/en not_active Withdrawn
- 2013-03-14 CN CN201711086139.2A patent/CN107789626A/en active Pending
- 2013-03-14 EP EP13763665.0A patent/EP2827851A4/en not_active Withdrawn
- 2013-03-14 MY MYPI2014702174A patent/MY175764A/en unknown
- 2013-03-14 KR KR1020187038194A patent/KR20190003840A/en not_active Application Discontinuation
- 2013-03-14 SG SG11201500409SA patent/SG11201500409SA/en unknown
- 2013-03-14 RU RU2014142066/15A patent/RU2599017C2/en not_active IP Right Cessation
- 2013-03-14 MX MX2014011129A patent/MX2014011129A/en unknown
- 2013-03-14 JP JP2015501785A patent/JP2015510936A/en active Pending
- 2013-03-14 CN CN201380015025.2A patent/CN104321056A/en active Pending
- 2013-03-14 AU AU2013235507A patent/AU2013235507B2/en not_active Ceased
- 2013-03-14 NZ NZ628079A patent/NZ628079A/en not_active IP Right Cessation
- 2013-03-14 CA CA2866755A patent/CA2866755A1/en not_active Abandoned
- 2013-03-14 RU RU2016133305A patent/RU2016133305A/en not_active Application Discontinuation
- 2013-03-14 NZ NZ714662A patent/NZ714662A/en not_active IP Right Cessation
- 2013-03-14 WO PCT/US2013/031617 patent/WO2013142274A1/en active Application Filing
- 2013-03-14 KR KR20147024604A patent/KR20140134284A/en active Search and Examination
- 2013-03-14 BR BR112014020113A patent/BR112014020113A8/en not_active Application Discontinuation
- 2013-03-14 KR KR1020177002422A patent/KR20170015537A/en active Application Filing
-
2014
- 2014-08-11 ZA ZA2014/05862A patent/ZA201405862B/en unknown
- 2014-08-21 ZA ZA2014/06146A patent/ZA201406146B/en unknown
- 2014-09-17 MX MX2019008817A patent/MX2019008817A/en unknown
-
2015
- 2015-05-27 HK HK15105034.0A patent/HK1204553A1/en unknown
- 2015-05-27 HK HK18110965.0A patent/HK1251469A1/en unknown
-
2016
- 2016-05-04 JP JP2016092868A patent/JP2016172752A/en active Pending
-
2017
- 2017-05-11 AU AU2017203139A patent/AU2017203139B2/en not_active Ceased
- 2017-05-15 AU AU2017203246A patent/AU2017203246B2/en not_active Ceased
- 2017-09-20 JP JP2017179685A patent/JP2018024693A/en active Pending
-
2018
- 2018-03-10 HK HK18103371.3A patent/HK1243921A1/en unknown
- 2018-05-15 JP JP2018093416A patent/JP2018138602A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ714288A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
MX2016001037A (en) | Inhibitors of transcription factors and uses thereof. | |
IL236892B (en) | Combination of immunoconjugate and antibody for use in therapy, pharmaceutical composition and kit comprising same | |
DOP2014000031A (en) | 4- (8-METOXI-1 - ((1-METOXIPROPAN-2-IL) -2- (TETRAHIDRO-2H-PIRAN-4-IL) -1H-IMIDAZO [4,5-C] QUINOLIN-7-IL) -3,5-DIMETHYLISOXAZOL AND ITS USE AS A BROMODOMINIUM INHIBITOR | |
MX2015017964A (en) | Bromodomain inhibitors. | |
HK1220631A1 (en) | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX366899B (en) | New compounds. | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
EA033311B1 (en) | Benzoxaborole derivatives as antibacterial agents | |
EP2617425A4 (en) | Pharmaceutical association for treating and/or preventing myoma and/or endometriosis, use of resveratrol and progestogen, pharmaceutical composition for treating and/or preventing myoma and/or endometriosis, medicament for treating and/or preventing myoma and/or endometriosis, kit and method for treating and/or preventing myoma and/or endometriosis | |
WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
MX2014008284A (en) | Delayed-release formulation for reducing the frequency of urination and method of use thereof. | |
PH12015501982A1 (en) | Pharmaceutical compositions comprising everolimus | |
MX2014008283A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof. | |
GB201014391D0 (en) | Drug composition and its use in therapy | |
WO2014076568A3 (en) | Pharmaceutical compositions of cetp inhibitors | |
HK1197235A1 (en) | Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders | |
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
HK1191654A1 (en) | Sterol derivatives, method for preparing same, pharmaceutical compositions containing same and use thereof for the treatment of multiple glioblastomas | |
MX2016005092A (en) | Vaginal inserted estradiol pharmaceutical compositons and methods. | |
WO2011101634A3 (en) | Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist | |
MX2016016039A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof. | |
TN2011000352A1 (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative | |
TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 MAR 2020 BY GRIFFITH HACK Effective date: 20170328 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2021 BY CPA GLOBAL Effective date: 20200424 |
|
LAPS | Patent lapsed |